Expression of P57(kip2) and cyslinE proteins in human pancreatic cancer / 中华医学杂志(英文版)
Chinese Medical Journal
;
(24): 944-946, 2003.
Artigo
em Inglês
| WPRIM
| ID: wpr-294197
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the effects of p57(kip2) and cyclinE proteins on the genesis and progression of human pancreatic cancer.</p><p><b>METHODS</b>The expression of p57(kip2) and cyclinE proteins in tumor tissues and adjacent tissues of pancreatic cancer in 32 patients was detected by SP immunohistochemical technique.</p><p><b>RESULTS</b>The p57(kip2) protein positive-expression rate in tumor tissues of pancreatic cancer was 46.9%, which was lower than that in adjacent pancreatic tissue (P < 0.05). The p57(kip2) protein positive-expression correlated significantly with tumor cell differentiation (P < 0.05) and did not correlate significantly with lymph node metastasis (P > 0.05). The cyclinE positive-expression rate in tumor tissues was 68.8%, which was higher than that in adjacent pancreatic tissues (P < 0.05). The cyclinE positive-expression also correlated significantly with tumor cell differentiation and lymph node metastasis (P < 0.05). The cyclinE protein positive-expression rate in the tumor tissues of the p57(kip2) protein positive-expression group was lower than that in the p57(kip2) protein negative-expression group, and there were no significant correlation between the two groups (r = -0.112, P > 0.05).</p><p><b>CONCLUSION</b>Decreased expression of the p57(kip2) protein and/or over-expression of the cyclinE protein may play an important role in the genesis and progression of human pancreatic cancer.</p>
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Neoplasias Pancreáticas
/
Patologia
/
Imuno-Histoquímica
/
Proteínas Nucleares
/
Química
/
Ciclina E
/
Inibidor de Quinase Dependente de Ciclina p57
Limite:
Adulto
/
Idoso
/
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Chinese Medical Journal
Ano de publicação:
2003
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS